Articles tagged with Type I Interferons
Researchers at Shinshu University found that cardamom seed extract enhances the production of antiviral proteins called type I interferons, which play a crucial role in defending against viral infections. The study suggests that cardamom could be a potential source of antiviral treatment.
Researchers at the University of Maryland discovered a way to predict treatment success for cutaneous leishmaniasis, a devastating skin infection. By analyzing a patient's immune system, they identified a distinctive pattern that distinguishes responders from non-responders, with 90% accuracy.
Scientists from the University of Zurich created decoy molecules that bind to autoantibodies, preventing them from inhibiting type I interferons. This restoration restores antiviral effect on viruses like influenza, offering hope for treatment and reducing viral disease susceptibility.
A new study reveals that about two percent of the population develop autoantibodies against type 1 interferons, making them more susceptible to severe viral infections. The autoantibodies remain detectable in the blood for life and are associated with a compromised type 1 interferon system.
Researchers found auto-antibodies against type I interferons in severe and critical COVID-19 patients, compromising their immune response. This discovery highlights the importance of detecting these auto-antibodies in regular health checkups to better prepare for viral infections.
A study using induced pluripotent stem cells has revealed that inflammation triggered by retrotransposons and interferon signaling causes atherosclerosis in Werner syndrome patients. The researchers propose targeting the interferon signaling pathway as a potential treatment for reducing stroke and heart attacks.
Researchers found that modulating type 1 Interferon (IFN-I) signaling reduces SARS-CoV-2 replication and inflammation in rhesus macaques, offering new treatment strategies for COVID-19. The study also showed a significant reduction in viral loads with IFNmod treatment.
A study published in Cellular Immunology reveals that type 1 interferons impair the metabolic response to Mycobacterium tuberculosis, making patients with chronic TB more susceptible to infections. The research identifies these cytokines as a potential target for developing new treatments.
Cancer cells have been found to employ a strategy to evade the immune system's killer T cells by interacting with myeloid cells and suppressing type 1 interferon production. This natural pathway is crucial for recruiting killer T cells to combat cancer spread. Researchers hope to develop new therapeutic approaches, such as forcing tumo...
Researchers at Linköping University found that C-reactive protein has a beneficial function in systemic lupus erythematosus, reducing interferon activity and promoting milder disease. The study's findings suggest new treatment strategies to reduce immune complexes and elevated interferon levels.
Researchers investigated Aicardi-Goutières syndrome and found that viral RNA recognition drives uncontrolled interferon production. The immune system mistakenly attacks healthy cells due to the failure of safety mechanisms to distinguish between viral and host genetic material.
Researchers from Trinity College Dublin have identified an enhanced type I interferon response in women who resisted infection after exposure to hepatitis C. This finding has significant implications for understanding viral resistance and designing therapies to treat infected individuals.
Individuals with Down syndrome experience less frequent but more severe viral infections, attributed to increased type I interferon expression. This leads to hyperactive immune responses initially, followed by overcorrection, resulting in increased vulnerability late in the viral attack.
Experiments in cell cultures and mice showed that blocking the function of NSUN2 triggers a powerful innate immune response, dramatically lowering viral replication and protecting lung tissue. This finding could help change the approach to developing antiviral medications.
A team of researchers found that aged mice infected with SARS-CoV-2 exhibited impaired type I interferon signaling and reduced levels of type II interferon IFN-γ, leading to increased susceptibility to severe disease. Treatment with IFN-γ protected these animals from severe illness.
Researchers at Trinity College Dublin have identified a crucial protein, myeloid cell nuclear differentiation antigen (MNDA), that regulates type I interferon production in response to viral infections. This breakthrough discovery has significant implications for the development of new therapies to boost or suppress immune responses, p...
Researchers discovered that infections improve the production and function of naïve T cells, the body's first line of defense against disease. This mechanism involves interleukin 7 and MHC molecules, which signal naïve T cells to stay alive and receive optimal metabolic signals.
A new study at the University of Chicago has found that individuals of European and African genetic ancestry respond differently to influenza infection, with a stronger type I interferon pathway activation in those of European ancestry. This variation in immune response may contribute to disparities in influenza outcomes between differ...
A Yale team has discovered an RNA molecule, SLR14, that stimulates the body's early antiviral defense system to protect against SARS-CoV-2 variants. This therapy holds promise as a new class of RNA therapeutics for treating COVID-19 in immunocompromised patients.
A new study reveals that COVID toes symptoms are caused by an immune response involving high levels of autoantibodies and type I interferon. Endothelial cells also play a crucial role in the development of the condition, according to the research published in the British Journal of Dermatology.
Scientists at Hokkaido University have developed a lipid nanoparticle that delivers immune-signaling molecules into liver macrophage cells to overcome resistance to anti-tumor immunotherapy. This approach has shown promise in mice experiments and could lead to the development of an adjuvant treatment for cancer patients.
Researchers found that a family of proteins enhances the immune response to HIV, Ebola and Zika by boosting signals sent within immune cells. This discovery has implications for potential broad antiviral therapy.
A new study by Ivan Zanoni at Boston Children's Hospital reveals a complex picture of interferon production in mild versus severe COVID-19. The researchers found that different types of interferons have opposite roles in the upper and lower respiratory tract, and that specific interferons determine disease severity.
A monoclonal antibody targeting plasmacytoid dendritic cells has shown promise in reducing cutaneous lupus symptoms. The treatment, VIB7734, significantly reduced pDC frequencies and type 1 interferon activity in patients with autoimmune diseases.
Researchers found that over 10% of young, healthy individuals with severe COVID-19 have misguided antibodies attacking their immune system. A genetic mutation in type I interferon production is also common among these patients.
A study found that over 10% of people with severe COVID-19 have misguided antibodies attacking the immune system, while 3.5% carry genetic mutations impacting immunity. These groups lack effective immune responses crucial for protecting against viruses, leading to life-threatening pneumonia.
Researchers created a new mouse model to study SARS-CoV-2 infection and disease, accelerating the development of treatments and vaccines. The model suggests that type I interferon signaling may play a pathological role in COVID-19 respiratory inflammation.
A study reveals that fat cells' immune response amplifies inflammation, driving obesity-related disease. Type I Interferons produced by fat cells trigger a vicious cycle of inflammation, which can worsen metabolic issues and increase the risk of diseases like type 2 diabetes and COVID-19.
Scientists from TWINCORE published insights on processes involved in liver inflammation, highlighting the importance of Kupffer cells in regulating inflammatory responses. Type I interferons trigger Kupffer cells to take up infected cells and undergo apoptosis, while also delaying regeneration of immune cells.
A study published in Science Immunology suggests that Zika virus triggers an immune response that can cause abnormal placental development and restricted fetal growth. Researchers found that the immune system's antiviral proteins, known as type I interferons, can be detrimental to fetal development if present in excess.
New research reveals that type I interferons impair the humoral response to chronic viral infections, such as HCV and HIV. The study suggests that blocking B cell IFN-I receptors can restore antigen-specific responses, providing a potential therapeutic approach.
Researchers found that temporarily blocking type I interferon can restore immune function and speed up viral suppression in HIV-infected mice. This approach may help eradicate HIV throughout the body when combined with antiretroviral therapy.
Researchers have identified a type I interferon marker that can predict patients with an increased risk of HCV relapse after antiviral therapy. Patients who maintain a strong type I interferon response are more likely to remain HCV-free.
Scientists at ETH Zurich have identified a mechanism that protects immune cells from natural killer cells. Type I interferon receptors play a crucial role in this process, and its absence can lead to the elimination of healthy immune cells. This discovery may have implications for understanding autoimmune diseases.
Researchers have identified plasmacytoid dendritic cells (pDCs) as a key producer of type I interferons in lupus, which can be targeted to prevent autoimmunity. Blocking this pathway may offer a potent weapon against the disease.
A novel DNA-sensing mechanism plays a role in the innate immune response to Plasmodium falciparum, the parasite that causes malaria. The study identifies an unknown receptor coupling to molecules linked with DNA-mediated type I interferon production, suggesting a broader impact on infectious diseases.
Researchers have identified NLRC5 as a key regulator of two critical immune pathways, NF-κB and type I interferon signaling. Reducing NLRC5 levels leads to increased immune responses and antiviral immunity, highlighting its role in regulating innate immunity.
A recent study published in the Journal of Experimental Medicine reveals that type I interferons are essential for combating Chikungunya virus infection. The unexpected finding is that fibroblasts, not immune cells, produce the virus-fighting proteins during infection.
A new study published in the Journal of Leukocyte Biology suggests that interferon can improve the effectiveness of the current tuberculosis vaccine by enhancing dendritic cell function. The research found that type I interferon stimulated dendritic cells to produce a stronger immune response against Mycobacterium tuberculosis.
The Baylor Research Institute has received a $6.2 million grant to establish a Center for Lupus Research, which will focus on understanding the immune system's role in lupus. The center aims to identify how lupus alters cells of the immune system, leading to abnormal protein levels and disease activity.
Researchers at VIB have discovered the mechanism behind reduced inflammation in mice, which produces just enough interferons to activate the immune system against bacteria. This finding is relevant to the quest for new therapeutics for bacterial infections and may provide a breakthrough in combating these deadly diseases.
Researchers discovered that TRAF3 is essential for producing type I interferons and IL-10, a protein preventing inflammation. Cells lacking TRAF3 over-produce inflammatory proteins, highlighting its role in controlling the immune response to viruses.